Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Conestat Alfa→

Conestat Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
80295-38-1
Molecular formula
C2115H3251N561O648S15
Molecular weight
~105000 g/mol
Drug class
Recombinant C1 esterase inhibitorcomplement and contact-system pathway regulator
Mechanism of action
Recombinant human C1 esterase inhibitor suppresses plasma kallikrein and activated factor XII, reducing bradykinin formation and vascular permeability in hereditary angioedema.
Indications / reported uses
  • Treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents under the US RUCONEST indication; not for routine prophylaxis and requires product-specific hypersensitivity precautions

Sources: US DailyMed — RUCONEST (conestat alfa) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Conestat Alfa Environmental Risk Assessment (ERA) (the Conestat Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.